Lv1
70 积分 2023-08-28 加入
Interlaboratory variation in PD-L1 positivity in non-small cell lung cancer patients: a nationwide study
14小时前
待确认
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study
1天前
已完结
CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors
2天前
已完结
Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer
5个月前
已完结
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages
6个月前
已完结
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
7个月前
已完结
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review
7个月前
已完结
Ptk7 as a direct and tumor stroma target in multiple solid malignancies
8个月前
已关闭
OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001)
8个月前
已完结
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: First-in-human dose-escalation study
9个月前
已完结
皖公网安备34019202002308
